Oregon Patent of the Month – October 2023

xBiologix, Inc. uses synthetic biology and novel materials to create advanced infectious disease diagnostics. The company is currently focused on non-invasive COVID-19 diagnostics. Within this mission, the company has been granted a patent for rapid detection tests (RDT) preloaded with detection particles.

The xBiologix RDT apparatus is a marvel of modern science, designed to enhance the accuracy, sensitivity, and efficiency of diagnostic tests. It boasts a substrate, a test region, and a set of capture agents that can bind to target analytes in biological samples. What truly sets this apparatus apart is its incorporation of two sets of detection particles, each equipped with distinct detectable labels.

One set of detection particles showcases a first detectable label, while the other features a second detectable label. The genius lies in their functionality – these labels are configured to bind to the target analyte. This dual-label approach not only increases the test’s accuracy but also ensures that even the tiniest concentrations of the analyte are detected. This is a game-changer, especially when dealing with viruses such as COVID-19.

In a world grappling with the ongoing pandemic, xBiologix’s invention brings hope by making rapid and accurate testing widely accessible. The test region can preload the first set of detection particles, creating a signal below the detection threshold. When exposed to a biological sample, this signal interacts with the second set of detection particles, providing an additive effect. Once the detection threshold is reached, the result becomes visible, offering a fast and precise diagnosis in just minutes.

This innovative approach isn’t confined to COVID-19 diagnostics alone. xBiologix is pioneering non-invasive, scalable diagnostics for a wide range of applications. Their synthetic biology platform reduces background noise, increases binding capacity, and lowers the limit of detection, promising diagnostics that are both cost-effective and precise.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts